Final Meeting Slides (click on title to download slides as pdf document)
FRIDAY, OCTOBER 30, 2009
Session I: Basic knowledge
Session chair E. Van Cutsem
13:40-14:05 Understanding the process of angiogenesis and cancer
Michael Schmidt, Belgium
14:10-14:35 Predictive markers for activity and toxicity
Emile Voest, The Netherlands
14:40-15:05 Anti-angiogenic agents on the horizon
Henk Verheul, The Netherlands
15:10-15:35 Tumor rebound: is there clinical evidence?
David Miles, United Kingdom
15:40-16:05 Key Note Lecture: Mechanism of resistance to angiogenesis inhibitors
Napoleone Ferrara, USA
Session II: Imaging tools for determining the activity of angiogenesis inhibitors
Session chair M. Aapro
16:30-16:50 MRI
Anwar Padhani, United Kingdom
16:55-17:15 Ultrasound
Nathalie Lassau, France
Session III: Lung and Prostate cancer
Session chair J. Bellmunt
17:20-17:40 Angiogenesis inhibition in Prostate cancer
Joaquim Bellmunt, Spain
17:45-18:05 Angiogenesis inhibition in Lung cancer
Jürgen Wolf, Germany
SATURDAY, OCTOBER 31, 2009
Session IV: RCC and Breast cancer
Session chair M. Aapro
08:30-08:50 Angiogenesis inhibition in RCC
Camillo Porta, Italy
08:55-09:15 Other biologicals, incl. mToR in RCC
Joaquim Bellmunt, Spain
09:20-09:40 Angiogenesis inhibition in Breast cancer
Nadia Harbeck, Germany
Session V: GI-Cancer
Session chair M. Ducreux
10:15-10:45 Angiogenesis inhibition in metastatic colorectal cancer
Eric Van Cutsem, Belgium
10:50-11:10 Angiogenesis inhibition & surgery in colorectal cancer
Theo Ruers, The Netherlands
11:15-11:35 Angiogenesis inhibition in adjuvant treatment of colorectal cancer
Aimery De Gramont, France
11:40-12:00 Angiogenesis inhibition in gastric cancer
Michel Ducreux, France
Session VI: Emerging Indications and Drugs
Session chair E. Voest
12:05-12:20 Angiogenesis inhibition in Glioblastoma
Roger Stupp, Switzerland
12:25-12.40 Angiogenesis inhibition in Ovarian cancer
Andrew Clamp, United Kingdom
12:45-13:00 Angiogenesis inhibition in combination with Radiotherapy
Christopher Willett, USA
13:05-13:20 Differential Drug safety in anti-angiogenic therapy
Jean-Philippe Spano, France
